Last Update Time:
12-Mar-2025 10:02:44
ISIN:
INE361B01024
Sector:
Healthcare
Symbol:
DIVISLAB
Divi's Laboratories Limited
₹5,504.45
₹-41.80
(-0.75%)
▼
Prev. Close
₹5,546.25
Open
₹5,525.00
Close
₹0.00
Range
₹5,229.23 - ₹5,779.67
High
₹5,557.95
Low
₹5,481.70
Ind. Close
₹0.00
VWAP
₹5,512.46
The current stock price of Divi's Laboratories Limited is ₹5,504.45, with a target price range between ₹5,229.23 and ₹5,779.67. The stock has experienced a price change of ₹-41.80 (-0.75%), reflecting recent market volatility.
Today's opening price was ₹5,525.00, while the previous close stood at ₹5,546.25.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Divi's Laboratories Limited Price Chart
Divi's Laboratories Limited Pre Open Market Overview: 12-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 5525
- Previous Close Price: 5546.25
- Change: -21.25%
- Total Traded Volume: 273
- Total Buy Quantity: 814
- Total Sell Quantity: 807
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 5,510.00 | 50.00 | 0.00 |
| 5,521.00 | 100.00 | 0.00 |
| 5,522.00 | 50.00 | 0.00 |
| 5,522.25 | 15.00 | 0.00 |
| 5,525.00 | 78.00 | 0.00 |
| 5,529.00 | 0.00 | 5.00 |
| 5,539.00 | 0.00 | 10.00 |
| 5,546.25 | 0.00 | 3.00 |
| 5,549.95 | 0.00 | 1.00 |
| 5,555.00 | 0.00 | 1.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 5,504.70 | 7 | 5,506.45 | 3 |
| 5,504.65 | 8 | 5,506.50 | 2 |
| 5,504.35 | 4 | 5,506.80 | 2 |
| 5,504.20 | 1 | 5,507.15 | 2 |
| 5,504.05 | 36 | 5,507.20 | 1 |
Total Buy Quantity: 814
Total Sell Quantity: 807
Shareholding Patterns of Divi's Laboratories Limited
Key Trade Statistics of Divi's Laboratories Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.29 |
| Traded Value (₹ Cr.) | 16.03 |
| Total Market Cap (₹ Cr.) | 146,125.85 |
| Free Float Market Cap (₹ Cr.) | 69,802.02 |
| Impact cost | 0.03 |
| Quantity Traded | 211,471.00 |
| Deliverable Quantity | 108,027.00 |
| % of Quantity to Traded | 51.08 |
| Security VaR | 10.61 |
| Index VaR | N/A |
| VaR Margin | 10.61 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 14.11 |
| Face Value | 2 |
Key Price Statistics of Divi's Laboratories Limited
The 52-week high for Divi's Laboratories Limited was ₹6,285.45, recorded on 03-Dec-2024. On the other hand, the 52-week low stands at ₹3,350.00, with the lowest value recorded on 27-Mar-2024.
The upper band for trading is ₹6,100.85, and the lower band is ₹4,991.65. The price band is No Band%.
The stock's daily volatility stands at 1.68, while the annualized volatility is 32.10. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (03-Dec-2024) | 6,285.45 |
| 52 Week Low (27-Mar-2024) | 3,350.00 |
| Upper Band | 6,100.85 |
| Lower Band | 4,991.65 |
| Price Band (%) | No Band |
| Daily Volatility | 1.68 |
| Annualised Volatility | 32.10 |
| Tick Size | 0.05 |
Key Securities Statistics of Divi's Laboratories Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 12-Mar-2003 |
| Adjusted P/E | 71.23 |
| Symbol P/E | 71.23 |
| Index | NIFTY NEXT 50 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Divi's Laboratories Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Divi's Laboratories Limited
| Subject | Date |
|---|---|
| Shareholders meeting | 07-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 07-Feb-2025 |
| Copy of Newspaper Publication | 05-Feb-2025 |
| Notice Of Shareholders Meetings-XBRL | 04-Feb-2025 |
| Shareholders meeting | 04-Feb-2025 |
| Copy of Newspaper Publication | 04-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 03-Feb-2025 |
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 03-Feb-2025 |
Corporate Actions of Divi's Laboratories Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 2 | Dividend - Rs 30 Per Share | 02-Aug-2024 |
| 2 | Dividend - Rs 30 Per Share | 11-Aug-2023 |
| 2 | Dividend - Rs 30 Per Share | 11-Aug-2022 |
| 2 | Dividend - Rs 20 Per Share | 17-Aug-2021 |
| 2 | Annual General Meeting | 04-Sep-2020 |
| 2 | Interim Dividend - Rs 16 Per Share | 25-Feb-2020 |
| 2 | Annual General Meeting/Dividend - Rs 16 Per Share | 14-Aug-2019 |
| 2 | Annual General Meeting/Dividend- Rs 10 Per Share | 31-Aug-2018 |
| 2 | Annual General Meeting/Dividend - Rs 10/- Per Share | 15-Sep-2017 |
| 2 | Annnual General Meeting | 18-Aug-2016 |
| 2 | Interim Dividend - Rs 10/- Per Share (Purpose Revised) | 17-Mar-2016 |
| 2 | Bonus 1:1 | 23-Sep-2015 |
| 2 | Annual General Meeting/Dividend - Rs 20/- Per Share | 06-Aug-2015 |
| 2 | Annual General Meeting / Dividend - Rs 20/- Per Share | 31-Jul-2014 |
| 2 | Annual General Meeting/Dividend Rs 15/- Per Share | 25-Jul-2013 |
| 2 | Annual General Meeting/ Dividend Of Rs. 13 Per Share | 26-Jul-2012 |
| 2 | Annual General Meeting And Dividend Rs.10/- Per Share | 16-Jun-2011 |
| 2 | Annual General Meeting And Dividend Rs.6/- Per Share | 02-Jul-2010 |
| 2 | Bonus-1:1 | 30-Jul-2009 |
| 2 | Agm/Div-Rs.6/- Per Share | 15-Jun-2009 |
Board Meetings of Divi's Laboratories Limited
Financial Results of Divi's Laboratories Limited
Company Directory of Divi's Laboratories Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.divislaboratories.com | Registered Office | 1-72/23(P)/DIVIS/303, Divi Towers, Cyber Hills Gachibowli | HYDERABAD |
| www.divislaboratories.com | Transfer Agent | M/s. Kfin Technologies Private Limited Selenium Tower B, Plot No 31&32 Financial Dist, Nanakramguda Gachibowli, Hyderabad | N/A |
Insider Trading of Divi's Laboratories Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Sridhar Donepudi | 3070000 | Sell |
| 7(2) | Y K Chowdary | 8223600 | Sell |
| 7(2) | Y. Sreedevi | 8223600 | Buy |
| 7(2) | P. Rama Sekhar | 3002870 | Buy |
| 7(2) | S Rajani | 621000 | Sell |
| 7(2) | DIVI MADHUSUDANA RAO | 30356000 | Sell |
| 7(2) | M.Ramesh Babu | 3011000 | Sell |
| 7(2) | Ch. Venu | 1198500 | Sell |
| 7(2) | L. Lakshmi | 8876600 | Buy |
| 7(2) | Y. KAMALAKAR | 4017500 | Sell |
| 7(2) | K. Sridevi | 542500 | Sell |
| 7(2) | K. Sridevi | 1282750 | Sell |
| 7(2) | K. Sridevi | 3050480 | Sell |
| 7(2) | AML Punna Rao | 13500000 | Sell |
| 7(2) | A. Lakshmi | 13500000 | Buy |
| 7(2) | Nimmagadda Venkata Anirudh | 69242231 | Sell |
| 7(2) | Nimmagadda Venkata Anirudh | 49275000 | Sell |
| 7(2) | M.Ramesh Babu | 9809701 | Sell |
| 7(2) | DIVI MADHUSUDANA RAO | 58657680 | Sell |
| 7(2) | Y. RAMA DEVI | 3875000 | Sell |
Annual Reports of Divi's Laboratories Limited
Investor Complaints of Divi's Laboratories Limited
Event Calendar of Divi's Laboratories Limited
| Purpose | Details |
|---|---|
| Results/Dividend | Inter-alia, to consider and approve the audited financial results for the year ended March 31, 2010 and to recommend Dividend on Equity Shares for the Year ended March 31, 2010. |
| Results/Dividend | Inter-alia, to consider and approve the audited financial results for the year ended March 31, 2011 and to recommend Dividend on Equity Shares for the Year ended March 31, 2011, if any. |
| Results/Dividend | Inter-alia, to consider and approve the audited financial results for the year ended March 31, 2012 and to recommend Dividend on Equity Shares for the year ended March 31, 2012, if any. |
| Results | To consider and approve ,inter alia , the un-audited financial results for the third quarter ended December 31, 2012. |
| Results/Dividend | Inter-alia, to consider and approve the audited financial results for the year ended March 31, 2013 and to recommend Dividend on Equity Shares for the year ended March 31, 2013, if any. |
| Results/Dividend | Inter-alia, to consider and approve the audited financial results for the year ended March 31, 2013 and to recommend Dividend on Equity Shares for the year ended March 31, 2013, if any. |
| Results | To consider and approve, inter-alia, the un-audited financial results for the first quarter ended June 30, 2013. |
| Results | To consider and approve, inter-alia, the un-audited financial results for the half year and quarter ended September 30, 2013. |
| Results | to consider and approve, inter-alia, the un-audited financial results for the quarter and nine months ended December 31, 2013. Further inform you that the Trading Window for dealing in securities of the Company shall remain closed for insiders of the company from January 27, 2014 to February 05, 2014 (both days inclusive) as per the Code of Conduct of the Company under the SEBI Prohibition of Insider Trading Regulations, 1992. |
| Results/Dividend | inter-alia, to consider and approve the audited financial results for the year ended 31st March 2014 and to recommend Dividend on Equity Shares for the year ended March 31, 2014, if any. We further inform you that the Trading Window for dealing in securities of the Company shall remain closed for insiders of the company from May 17, 2014 to May 26, 2014 (both days inclusive) as per the Code of Conduct of the Company under the SEBI Prohibition of Insider Trading Regulations, 1992. |
| Results | To consider and approve, inter-alia, the un-audited financial results for the first quarter ended June 30, 2014. We further inform you that the Trading Window for dealing in securities of the Company shall remain closed for insiders of the company from August 4, 2014 to August 13, 2014 (both days inclusive) as per the Code of Conduct of the Company under the SEBI Prohibition of Insider Trading Regulations, 1992. |
| Results | To consider and approve, inter-alia, the un-audited financial results for the quarter and half-year ended September 30, 2014. |
| Results | To consider and approve, inter-alia, the un-audited financial results for the quarter and nine months ended December 31, 2014. |
| Results/Dividend | Inter-alia, to consider and approve the audited financial results for the year ended March 31, 2015 and to recommend Dividend on Equity Shares for the year ended March 31, 2015, if any. |
| Results | To consider and approve, inter-alia, the un audited financial results for the first quarter ended June 30, 2015. |
| Results | to consider and approve, inter-alia, the un-audited financial results for the first quarter ended June 30, 2015. |
| Results | to consider and approve, inter-alia, the un-audited financial results for the quarter and half-year ended September 30, 2015. |
| Results | To consider and approve, inter-alia, the un-audited financial results for the quarter and nine months ended December 31, 2015. |
| Dividend | inter-alia, to consider and declare interim dividend on the paid-up equity share capital of the company for the financial year 2015-16. |
| Results/Dividend | Inter-alia, to consider and approve the audited financial results for the year ended March 31, 2016 and to recommend a final Dividend, if any, on Equity Shares for the financial year 2015-16. |
| Results | to consider and approve, inter-alia, the un-audited financial results for the first quarter ended June 30, 2016. |
| Results | To consider and approve, inter-alia, the un-audited financial results for the quarter and half-year ended 30th September 2016. |
| Results | To consider and approve, inter-alia, the un-audited financial results for the quarter and nine months ended December 31, 2016. |
| Results/Dividend | Inter-alia, to consider and approve standalone and consolidated audited financial results for the year ended March 31, 2017 and to recommend dividend, if any, on Equity Shares for the financial year 2016-17. |
| Results | inter-alia, to consider and approve un-audited financial results for the quarter ended June 30, 2017. |
| Results | To consider and approve, inter-alia, the un-audited financial results for the quarter and half-year ended September 30, 2017. |
| Results | To consider and approve, inter-alia, the un-audited financial results for the quarter and nine months ended December 31, 2017. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Dividend | To consider dividend |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2021 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results | DIVISLAB : 11-Feb-2022 : The Company has informed the Exchange that a Board meeting to be held on February 04, 2022 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on February 11, 2022, To consider and approve the financial results for the period ended December 31, 2021 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Divi's Laboratories Limited has informed the Exchange about Board Meeting to be held on 12-Aug-2022 to consider financial statements for the period ended June 2022 |
| Financial results | Divi's Laboratories Limited has informed the Exchange about Board Meeting to be held on 07-Nov-2022 to consider financial statements for the period ended September 2022 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2022 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2023 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of Divi's Laboratories Limited
Voting Results of Divi's Laboratories Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 06-MAR-2025 | Postal Ballot | Re-appointment of Dr. Kiran S. Divi (DIN: 00006503) as Whole-time Director and Chief Executive Officer of the Company |
| 06-MAR-2025 | Postal Ballot | Re-appointment of Dr. Kiran S. Divi (DIN: 00006503) as Whole-time Director and Chief Executive Officer of the Company |
| 12-AUG-2024 | AGM | To consider and adopt the audited financial statements of the Company, both standalone and consolidated, for the financial year ended March 31, 2024, and the reports of the Board of Directors￢ﾀﾙ and Auditors￢ﾀﾙ thereon |
| 12-AUG-2024 | AGM | To re-appoint Mr. K.V. Chowdary (DIN: 08485334) as an Independent Director of the Company w.e.f. January 04, 2025. |
| 12-AUG-2024 | AGM | To re-appoint Mr. N.V. Ramana (DIN: 00005031) as Executive Director of the Company w.e.f. December 26, 2024. |
| 12-AUG-2024 | AGM | To re-appoint Dr. Murali K. Divi (DIN: 00005040) as Managing Director of the Company w.e.f. October 10, 2024 |
| 12-AUG-2024 | AGM | To appoint Dr. Rajendra Kumar Premchand, (DIN: 00895990), as an Independent Director of the Company w.e.f. May 25, 2024. |
| 12-AUG-2024 | AGM | To appoint a director in place of Dr. Kiran S. Divi (DIN: 00006503), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment |
| 12-AUG-2024 | AGM | To appoint a director in place of Mr. N.V. Ramana (DIN: 00005031), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment |
| 12-AUG-2024 | AGM | To declare dividend of Rs. 30/- per Equity Share of face value Rs. 2/-each (i.e. @ 1500%) for the financial year ended March 31, 2024 |
| 04-APR-2024 | Postal Ballot | Reappointment of Prof. Sunaina Singh (DIN: 08397250) as an Independent Director of the Company for a second term of 5 (five) consecutive years |
| 04-APR-2024 | Postal Ballot | Approval to hold and continue to hold office or place of profit by Mr. S. Swaroop Krishna in the Company |
| 04-APR-2024 | Postal Ballot | Appointment of Dr. S. Devendra Rao (DIN: 10481393) as Whole-time Director, designated as ￢ﾀﾘWhole-time Director (Manufacturing)￢ﾀﾙ of the Company and approval of the remuneration payable to him |
| 28-AUG-2023 | AGM | To consider and adopt the audited financial statements of the Company, both standalone and consolidated, for the financial year ended March 31, 2023, and the reports of the Board of Directors￢ﾀﾙ and Auditors￢ﾀﾙ thereon |
| 28-AUG-2023 | AGM | To appoint a director in place of Ms. Nilima Prasad Divi (DIN:06388001), who retires by rotation at this Annual General Meeting and being eligible, offers herself for re-appointment |
| 28-AUG-2023 | AGM | To appoint a director in place of Dr. Kiran S. Divi (DIN: 00006503), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment |
| 28-AUG-2023 | AGM | To declare dividend of Rs.30/- per Equity Share of face value Rs.2/-each (i.e. @ 1500%) for the financial year ended March 31, 2023 |
| 22-AUG-2022 | AGM | To consider and adopt the audited financial statements of the Company, both standalone and consolidated, for the financial year ended March 31, 2022, and the reports of the Board of Directors￢ﾀﾙ and Auditors￢ﾀﾙ thereon. |
| 22-AUG-2022 | AGM | To appoint a director in place of Mr. N.V. Ramana (DIN 00005031), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment. |
| 22-AUG-2022 | AGM | To declare dividend of Rs. 30/- per Equity Share of face value Rs. 2/- each (i.e. @1500%) for the financial year ended March 31, 2022. |
FAQs on Divi's Laboratories Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.